



PRODUCT: **Braftovi® Mektovi®**

COMPANY: Pfizer Inc.

THERAPEUTIC AREA & INDICATION:

Treatment of metastatic melanoma

---

#### ABOUT THE PRODUCT

Metastatic melanoma is one of the most serious and life-threatening types of skin cancer. There are a variety of gene mutations that can lead to metastatic melanoma, the most common being *BRAF*, which occurs in approximately half of patients with unresectable or metastatic disease. BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) are kinase inhibitors indicated for use in combination for the treatment of patients with unresectable or metastatic melanoma with a *BRAF* V600E or V600K mutation as detected by an FDA-approved test. BRAFTOVI is not indicated for treatment of patients with wild type *BRAF* melanoma.